PerkinElmer acquires SIRION Biotech, which develops and produces viral vectors for cell and gene therapy research. The deal is expected to close in Q3 2021. Terms of the deal were not disclosed.
PerkinElmer acquires SIRION Biotech, which develops and produces viral vectors for cell and gene therapy research. The deal is expected to close in Q3 2021. Terms of the deal were not disclosed. 
English (US) 